BIGG

Resultados: 17

WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection

The political declaration at the first United Nations (UN) high-level meeting on tuberculosis (TB) held on 26 September 2018 included commitments by Member States to four new global targets.3 One of these targets is to diagnose and treat 40 million people with TB in the 5-year period 2018–2022. The ap...

Latent TB infection: updated and consolidated guidelines for programmatic management

Background The programmatic management of latent tuberculosis infection (LTBI) in populations most at risk of developing TB remains a critical activity to disrupt Mycobacterium tuberculosis transmission, as identified in the End TB Strategy. LTBI is defined as a state of persistent immune response to sti...

Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update

The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

Clin. infect. dis; 63 (7), 2016
The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tube...

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

"BACKGROUND: Infantile wheezing is a common problem, but there are no guidelines for the evaluation of infants with recurrent or persistent wheezing that is not relieved or prevented by standard therapies. METHODS: An American Thoracic Society-sanctioned guideline development committee selected clinical...

The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin

Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...

WHO treatment guidelines for drug-resistant tuberculosis, 2016 update

In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...

Guidelines on the Management of Latent Tuberculosis Infection

The overall objective of the guidelines is to provide public health approach guidance on evidencebased practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. The guidelines are expected to provide the basis and rationale for the developmen...

Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB and HIV-prevalence settings: 2015 update

In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-mont...

The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance

The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...